Anaveon Presents Positive ANV600 Clinical Data at ASCO 2026, Seeks Partners for Oncology Portfolio
核心洞察
Anaveon (搜索) will present positive clinical data from its ANV600 (sunekafusp alpha (搜索)) Phase 1 study at ASCO 2026, showing manageable safety profile and encouraging early clinical activity including tumor shrinkage.
The company has strategically pivoted to focus on autoimmune and inflammatory diseases (搜索) and is actively seeking global partners for its legacy oncology portfolio through various structures.
ANV600 is a first-in-class PD-1 (搜索)-targeted IL-2R-βγ (搜索) agonist designed to selectively expand tumor-reactive T cells while reducing IL-2-associated toxicities, with potential in checkpoint inhibitor-resistant settings.
Swiss biotechnology company Anaveon (搜索) announced that positive clinical data from its legacy oncology asset ANV600 (sunekafusp alpha (搜索)) will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Following its strategic pivot to immunology, the company is actively seeking global development and commercialization partners for its oncology portfolio.
Novel PD-1-Targeted IL-2 Approach Shows Promise
ANV600 represents a first-in-class, non-blocking PD-1 (搜索)-targeted IL-2R-βγ (搜索) agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells while reducing the toxicities historically associated with IL-2 therapy. The drug binds PD-1 on a unique non-blocking epitope, distinct from that targeted by pembrolizumab and other PD-1 checkpoint inhibitors.
"ANV600 has delivered compelling clinical proof-of-mechanism and a promising safety-efficacy profile in patients with advanced solid tumors (搜索)," said Thaminda Ramanayake, Chief Executive Officer of Anaveon (搜索). "With strong interest from physicians at clinical sites for Phase 2 development, we believe this asset is ideally suited for a partner with the resources and expertise to bring it forward in CPI-resistant NSCLC (搜索) and other immuno-oncology indications."
EXPAND-1 Study Results Highlight Clinical Potential
Key results from the EXPAND-1 Phase 1 study, to be presented in poster format at ASCO, demonstrate several encouraging findings. The study showed a manageable safety profile both as monotherapy and in combination with pembrolizumab. Importantly, the trial provided clear proof-of-mechanism, demonstrating preferential proliferation of PD-1 (搜索)+ CD8+ T cells over regulatory T cells.
The study also revealed encouraging early clinical activity, including tumor shrinkage in a meaningful proportion of patients, encompassing both post-checkpoint inhibitor and checkpoint inhibitor-naïve populations. Patients experienced disease control and durable benefit, and researchers established a recommended Phase 2 dose.
Previous data presented at ESMO-IO in December showed three responses among 42 patients, though two dose-limiting toxicities and an unrelated death were observed.
Strategic Pivot and Partnership Opportunities
Anaveon (搜索) has strategically shifted its focus to autoimmune and inflammatory diseases (搜索), with its main priority now being ANV200 (搜索), a PD-1 (搜索) agonistic antibody for autoimmune diseases (搜索). The company's oncology portfolio also includes ANV700, a preclinical proximity-activated PD-1-targeted IL-21 fusion protein with potential for synergistic effects when combined with IL-2-based approaches.
The company is open to various partnering structures including license agreements, co-development arrangements, or acquisition for its oncology assets. ANV600 is positioned for use in checkpoint inhibitor-resistant and checkpoint inhibitor-relapsed settings, making it compatible with existing checkpoint inhibitors.
Competitive Landscape in IL-2 Field
The cytokine approach field has experienced both setbacks and recent renewed interest. Several discontinuations have occurred, including Nektar/Bristol Myers Squibb (搜索)'s IL-2 asset bempegaldesleukin. However, the field received a significant boost with Takeda (搜索)'s licensing of Innovent (搜索)'s anti-PD-1 (搜索) x IL-2 project IBI363 for $1.2 billion upfront, which is now in the pivotal MarsLight-11 trial.
Other PD-1 (搜索) x IL-2 contenders in development include Teva (搜索)'s TEV-56278 and Regeneron's REGN10597. Amgen's similarly acting latikafusp (AMG 256) no longer appears to be in development, while CD Biopharma (搜索)'s CD-001 is in phase 1 trials in China.
The ASCO presentation will take place on May 30, 2026, from 1:30 to 3:00 pm local time at Hall A, poster board 377, under the session title "Development Therapeutics-Immunotherapy."